We don't use the word hope lightly at SurvivorNet, but with regards to multiple myeloma, patients should truly be hopeful. We can say that because the specialists who’ve been driving the field for the past 20 years all believe that the treatments they now give to patients are drastically better than when they first began their careers. Both medicine and research are extremely promising for people who are recently or newly diagnosed with multiple myeloma. We are indeed at something of an inflection point.
“In multiple myeloma we’ve been blessed in the last twenty years with an extraordinary change in the natural history of the disease, by virtue of the introduction of novel agents–which are biologically targeted, biologically rational approaches to treatment–that have really superseded the older approaches of chemotherapeutics,” says Dr. Paul Richardson, Director of Clinical Research at the Dana-Farber Cancer Institute.
Read MoreLearn more about SurvivorNet's rigorous medical review process.
